Table 1.
Baseline patient characteristics at inclusion.
| Overall population n = 115 | HPV01 n = 49 | HPV02 n = 66 | p value | |
|---|---|---|---|---|
| Gender | ||||
| Female | 87 (75.7%) | 33 (67.3%) | 54 (81.8%) | 0.0738 |
| Male | 28 (24.3%) | 16 (32.7%) | 12 (18.2%) | |
| Age | ||||
| Mean (SD) | 60.2 (9.3) | 61.0 (9.8) | 59.5 (9.0) | 0.9142 |
| Median (min–max) | 60.0 (38.6;84.0) | 59.4 (38.7;84.0) | 60.0 (38.6;78.4) | |
| Q1–Q3 | 53.6–66.7 | 54.4–68.7 | 53.6–65.8 | |
| ECOG-PS | ||||
| 0 | 72 (62.6%) | 31 (63.3%) | 41 (62.1%) | 0.0072 |
| 1 | 37 (32.2%) | 12 (24.5%) | 25 (37.9%) | |
| 2 | 6 (5.2%) | 6 (12.2%) | 0 (0.0%) | |
| HIV status | ||||
| Negative | 109 (94.8%) | 45 (91.8%) | 64 (97.0%) | 0.3991 |
| Positive | 6 (5.2%) | 4 (8.2%) | 2 (3.0%) | |
| Chemoradiotherapy | ||||
| Missing | 5 | 5 | 0 | 0.5493 |
| No | 40 (34.0%) | 19 (37.5%) | 21 (31.8%) | |
| Yes | 70 (66.0%) | 25 (62.5%) | 45 (68.2%) | |
| Concomitant chemotherapy | (n = 70) | (n = 25) | (n = 45) | |
| Missing | 3 | 2 | 1 | 0.7706 |
| CDDP + 5FU | 7 (10.5%) | 1 (4.3%) | 6 (13.6%) | |
| Capecitabine | 1 (1.5%) | 0 (0.0%) | 1 (2.3%) | |
| MMC | 1 (1.5%) | 0 (0.0%) | 1 (2.3%) | |
| MMC + CDDP + 5FU | 1 (1.5%) | 0 (0.0%) | 1 (2.3%) | |
| MMC + Cape/5FU | 56 (83.6%) | 22 (95.7%) | 34 (77.3%) | |
| MMC + Cape + CDDP + 5FU | 1 (1.5%) | 0 (0.0%) | 1 (2.3%) | |
| Surgery | ||||
| Missing | 5 | 5 | 0 | 0.5887 |
| No | 89 (80.9%) | 35 (79.5%) | 54 (81.8%) | |
| Yes | 21 (19.1%) | 9 (20.5%) | 12 (18.2%) | |
| Stage | ||||
| Locally advanced | 25 (21.7%) | 19 (38.8%) | 6 (9.1%) | 0.0002 |
| Synchronous metastases | 29 (25.2%) | 13 (26.5%) | 16 (24.2%) | |
| Metachronous metastases | 61 (53.1%) | 17 (34.7%) | 44 (66.7%) | |
| Number of sites involved | ||||
| Mean (SD) | 2.3 (1.3) | 2.0 (1.3) | 2.4 (1.3) | 0.0600 |
| Median (min–max) | 2.0 (1.0;8.0) | 2.0 (1.0;8.0) | 2.0 (1.0;6.0) | |
| Q1–Q3 | 1.0–3.0 | 1.0–2.0 | 1.0–3.0 | |
| Type of treatment | ||||
| sDCF | 54 (47.0%) | 18 (36.7%) | 36 (54.6%) | 0.0285 |
| mDCF | 58 (50.4%) | 28 (57.2%) | 30 (45.4%) | |
| DCarboF | 3 (2.6%) | 3 (6.1%) | 0 (0.0%) | |
5FU, 5-fluorouracil; Cape, capecitabine; CDDP, cisplatin; DCarboF, docetaxel 40 mg/m2, carboplatin AUC 4, 5FU 2400 mg/m2, every 2 weeks; ECOG-PS, Eastern Cooperative Oncology Group performance status; mDCF, modified DCF; MMC, mitomycin; SD, standard deviation; sDCF, standard DCF.